<DOC>
	<DOCNO>NCT01930734</DOCNO>
	<brief_summary>Heart failure ( HF ) prevalent disease reach 1-2 % adult population develop country , 10 % patient 70 year . In past HF patient 5-year mortality rate 60-70 % HF high rate hospitalization disability lead HF epidemic . Treatment improvement past decade significantly reduce hospitalization mortality . However , increase subset patient ( &gt; 10 % ) advance HF symptom ( functional class III/IV ) current management strategy limit provide significant improvement morbidity , mortality quality life . Specialized HF clinic , implement comprehensive therapeutic approach , suggest beneficial population . However , design clinic variable different method follow-up , therapy supervision . Intermittent infusion dobutamine previously inconclusive regard symptom alleviation hemodynamic improvement raise concern increase mortality HF patient . Furthermore , evidence scope narrow since trial include inconsistent relatively high dobutamine dosage . Accordingly , current guideline provide specific recommendation dobutamine therapy stable HF patient , indication treatment limit acute HF hypotension sign hypoperfusion , alleviation symptom severely symptomatic patient stage D HF . The primary aim propose study evaluate impact intermittent low-dose dobutamine infusion clinical hemodynamic parameter advance HF patient treat tertiary heart failure clinic setting randomize clinical trial . We hypothesize intermittent therapy low-dose dobutamine associate improved functional capacity quality life among patient advanced heart failure , thereby provide evidence beneficial effect potentially important therapeutic regimen high risk population .</brief_summary>
	<brief_title>Outcome Safety Intermittent Dobutamine Infusion Day-Care Center Advanced Heart Failure Patients</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Dobutamine</mesh_term>
	<criteria>Age 18 Symptomatic HF NYHA IIIIV Left ventricular ejection fraction &lt; 30 % Maximal tolerate dosage Angiotensin receptor blocker ( ARB ) Angiotensin convert enzyme inhibitor ( ACEI ) , aldosterone antagonists Î²Blockers accord blood pressure , heart rate , renal function potassium level Prior implementation resynchronization therapy implantable defibrillator indicate ? ? Prior HF hospitalization past 12 month Unsatisfactory response intravenous diuretic hospitalization ambulatory care . Active ischemia Acute coronary syndrome cardiac surgery within 3 month Hemodynamic respiratory instability , systolic blood pressure 85mmHg , oxygen saturation 90 % rest Uncontrolled hypertension &gt; 180/110 mmHg Contraindication dobutamine therapy Hemodialysis therapy Malignant ventricular arrythmias Drug alcohol abuse Sepsis ongoing systemic infection Active myocarditis Severe valvular stenosis Noncompliance Lifethreatening extracardiac disease malignancy life expectancy 1 year Inability sign inform consent Participation another trial previous 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Heart Failure</keyword>
	<keyword>Dobutamine</keyword>
</DOC>